Gain Therapeutics Stock
Gain Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Gene Mack
- Employees
- 21
- Market cap
- $54 M
- IPO
- 19/03/2021
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement…
Gain Therapeutics stock: price history
1D
-5.3%
1W
-23.2%
1M
-26.7%
6M
-40.8%
YTD
-60.9%
1Y
-30.4%
2Y
-56.8%
5Y
-81.8%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~6% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Gain Therapeutics
Analyst assessment of Gain Therapeutics
PRICE TARGET LOW
US$5.00
CONSENSUS
US$5.00
MEDIAN
US$5.00
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
7
BUY
1
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 05/10/2026
Gain Therapeutics stock metrics
P/E
-2.52
P/B
4.78
EV/EBITDA
-2.16
RETURN ON EQUITY
-41.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.05
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.3%
FLOAT SHARES
42,363,970
AVG. DAILY VOLUME (30D)
464,299
Institutional holders
Comparable stocks
Frequently asked questions about Gain Therapeutics stock
What does Gain Therapeutics do?
Gain Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Gene Mack, the company employs around 21 people.
The IPO was on 19/03/2021; the stock trades on NASDAQ under the ticker GANX.
What do analysts say about Gain Therapeutics stock?
8 analysts rate the stock, the consensus is Buy (as of 05/10/2026).
The average price target is US$5.00, ranging from US$5.00 to US$5.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does Gain Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -6% stronger than usual.
Does Gain Therapeutics pay a dividend?
No, Gain Therapeutics currently does not pay a dividend.
Which stocks are comparable to Gain Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Gain Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Gain Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.